Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Demange

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
ACS Medicinal Chemistry Letters|June 19, 2024
A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR<sup>+</sup>CXCL-CXCR1/2 Pathway InhibitorOleksandr Grytsai, Maeva Dufies, Julie Le Du, et al.
Journal of Medicinal Chemistry|October 12, 2007
Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluationsAline Moulin, Luc Demange, Gilbert Bergé, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2019
Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agentEtienne Brachet, Aurore Dumond, Wang-Qing Liu, et al.
Journal of Medicinal Chemistry|March 23, 2007
Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1Luc Demange, Damien Boeglin, Aline Moulin, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2014
Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptorWang-Qing Liu, Valentino Megale, Lucia Borriello, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2021
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinomaAurore Dumond, Etienne Brachet, Jérôme Durivault, et al.
Cancer Letters|April 23, 2014
Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer modelLucia Borriello, Matthieu Montès, Yves Lepelletier, et al.
Theranostics|August 15, 2019
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatmentsMaeva Dufies, Oleksandr Grytsai, Cyril Ronco, et al.
Cancer Letters|November 8, 2017
NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft modelWang-Qing Liu, Yves Lepelletier, Matthieu Montès, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
ACS Medicinal Chemistry Letters|June 19, 2024
A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR<sup>+</sup>CXCL-CXCR1/2 Pathway InhibitorOleksandr Grytsai, Maeva Dufies, Julie Le Du, et al.
Journal of Medicinal Chemistry|October 12, 2007
Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo evaluationsAline Moulin, Luc Demange, Gilbert Bergé, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2019
Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agentEtienne Brachet, Aurore Dumond, Wang-Qing Liu, et al.
Journal of Medicinal Chemistry|March 23, 2007
Synthesis and pharmacological in vitro and in vivo evaluations of novel triazole derivatives as ligands of the ghrelin receptor. 1Luc Demange, Damien Boeglin, Aline Moulin, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2014
Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptorWang-Qing Liu, Valentino Megale, Lucia Borriello, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2021
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinomaAurore Dumond, Etienne Brachet, Jérôme Durivault, et al.
Cancer Letters|April 23, 2014
Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer modelLucia Borriello, Matthieu Montès, Yves Lepelletier, et al.
Theranostics|August 15, 2019
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatmentsMaeva Dufies, Oleksandr Grytsai, Cyril Ronco, et al.
Cancer Letters|November 8, 2017
NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft modelWang-Qing Liu, Yves Lepelletier, Matthieu Montès, et al.
Pageof 4